Back to Network
3
Shared Docs
3
Same-Page
3 / 3
Mentions
Document Mentions (3 shared documents)
2 mentions1 same-page
Page ?Same page
Takeaways from FOURIER "We've never been able to plumb these depths before." lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."
ply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2017 American College of Cardiology Scientific Session in Was
2 mentions1 same-page
Page ?Same page
L to lowest, 74 mg/dL). 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."
y Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was
2 mentions1 same-page
Page ?Same page
owest, 74 mg/dL). IIr 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD. of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. -These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."
Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was
Sponsored
Mutual Connections (15)
Entities connected to both Harvard Medical School and the Further Cardiovascular Outcomes Research
Jeffrey Epstein
PERSON155 w/ Harvard·3 w/ the
Lesley Groff
PERSON57 w/ Harvard·3 w/ the
Mount Sinai
ORGANIZATION3 w/ Harvard·3 w/ the
Brigham and Women's Hospital
ORGANIZATION4 w/ Harvard·2 w/ the
RS
Rony Shimony
PERSON3 w/ Harvard·3 w/ the
Icahn School of Medicine at Mount Sinai
ORGANIZATION3 w/ Harvard·3 w/ the
MS
Marc S. Sabatine
PERSON3 w/ Harvard·3 w/ the
SA
Sabatine
PERSON3 w/ Harvard·3 w/ the
GR
Giugliano RP
PERSON3 w/ Harvard·3 w/ the
Evolocumab
ORGANIZATION3 w/ Harvard·3 w/ the
American College of Cardiology 2017 Scientific Session
ORGANIZATION3 w/ Harvard·3 w/ the
Keech AC
ORGANIZATION3 w/ Harvard·3 w/ the
American Medical Communications
ORGANIZATION3 w/ Harvard·3 w/ the
Manalapan
LOCATION3 w/ Harvard·3 w/ the
Sabatine M. Primary
ORGANIZATION2 w/ Harvard·2 w/ the